Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
Of those vehicles, the ones that closed a merger.
Announced but not closed, and still hunting.
No closed vehicle here has both a stored price and a filed trust value to score it against.
2 vehicles on file, newest listing first
none appears on more than one · 1 vehicle carry no counterparty filing we have read
Patrick Crutcher will serve as a Director upon the effectiveness of this registration statement, of which this prospectus is a part. Mr. Crutcher has over 15 years experience establishing and building private and public biotechnology companies, with a focus on business development, precision therapeutics for rare diseases and biologics in drug development. Mr. Crutcher is currently the Founder Chairman of Mach5 Therapeutics, Inc., AstralBio, Inc., ImmuneStudio, Inc. and is a member of the board in CrossBridge Bio, Inc and Chima Bioventures LLC. He also co -founded Helicore Biopharma, Inc., an obesity company backed by Orbimed and Versant. Mr. Crutcher served as Co -Founder , CEO and director
This record is keyed to SEC CIK 0001754540 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 235 institutional-holder rows on these vehicles, under 94 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.